GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Dabomb Protein Biotech Corp (ROCO:6578) » Definitions » EBIT

Dabomb Protein Biotech (ROCO:6578) EBIT : NT$-25.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Dabomb Protein Biotech EBIT?

Dabomb Protein Biotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was NT$10.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-25.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dabomb Protein Biotech's annualized ROC % for the quarter that ended in Mar. 2024 was -0.20%. Dabomb Protein Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dabomb Protein Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1.53%.


Dabomb Protein Biotech EBIT Historical Data

The historical data trend for Dabomb Protein Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dabomb Protein Biotech EBIT Chart

Dabomb Protein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.01 14.22 -67.04 -42.48 -47.72

Dabomb Protein Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.19 -8.57 -25.04 -1.91 10.25

Competitive Comparison of Dabomb Protein Biotech's EBIT

For the Packaged Foods subindustry, Dabomb Protein Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dabomb Protein Biotech's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dabomb Protein Biotech's EV-to-EBIT falls into.



Dabomb Protein Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-25.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dabomb Protein Biotech  (ROCO:6578) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dabomb Protein Biotech's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-2.36 * ( 1 - 21.21% )/( (954.96 + 942.295)/ 2 )
=-1.859444/948.6275
=-0.20 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1401.896 - 24.87 - ( 429.454 - max(0, 356.768 - 778.834+429.454))
=954.96

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1400.002 - 33.929 - ( 423.778 - max(0, 310.229 - 779.714+423.778))
=942.295

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Dabomb Protein Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=40.984/( ( (579.808 + max(323.124, 0)) + (579.686 + max(320.537, 0)) )/ 2 )
=40.984/( ( 902.932 + 900.223 )/ 2 )
=40.984/901.5775
=4.55 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(50.551 + 20.233 + 277.443) - (24.87 + 0 + 0.23299999999995)
=323.124

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(44.117 + 27.597 + 282.752) - (33.929 + 0 + -5.6843418860808E-14)
=320.537

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dabomb Protein Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-25.277/1656.241
=-1.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dabomb Protein Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Dabomb Protein Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Dabomb Protein Biotech (ROCO:6578) Business Description

Traded in Other Exchanges
N/A
Address
Number 52, Gongye 3rd Road, Annan District, Tainan, TWN, 709
Dabomb Protein Biotech Corp is a company specializing in antibiotic alternatives, and use postbiotics to boost immune strength and excel in innovative fermentation for improved plant protein utility. Their portfolio of products which include DBT-100 LS and DBT-100 HT , Liqui-TIDE bandage and LACTOTIDES HEALTH A+.

Dabomb Protein Biotech (ROCO:6578) Headlines

No Headlines